NANOSTEM | New nanomaterials for neural stem cells drug delivery

Summary
Brain conditions such as neurodegenerative diseases, stroke and traumatic injuries are a mayor burden in modern society. Because neural stem cells (NSCs) can differentiate into new neural cells including neurons, the regulation of their proliferation, differentiation and migration represent a promising regenerative/therapeutic strategy. The hypothesis of NanoStem project is that novel nanoparticles (NPs) combined with recent identified/developed pharmaceuticals can be an efficient approach to control the biological activity of NSCs. The scientific project is organized in three work packages (WP), each focusing on specific objectives and containing well-defined deliverables. WP1 will focus on the synthesis of the nanomaterials and the uploading of the therapeutics. WP2 will take the best nanoparticles and focus more on the evaluation of the permeation and efficacy of the formulations against NSCs. WP3 will focus on in vivo studies to evaluate the formulations developed to tackle the brain and to assess their toxicity. The project will train 14 ESRs in areas including organic and polymer chemistry, cell biology, pharmacology, neuroscience, nanobiotechnology and clinical sciences. The project will also provide a substantial training program in complementary skills, targeting both professional and personal development, and translation of research and entrepreneurship. The project brings together six academic partners, one hospital and two industrial teams as full partners, complemented by four associate partners, one of which is an industrial team, distributed over a total of seven European Union member states. The consortium brings together groups with a very interdisciplinary expertise ranging from nanoparticle synthesis and characterization, computational modeling, in vitro BBB models and BBB transport, neural stem cells, animal testing and clinical expertise.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/764958
Start date: 01-06-2018
End date: 31-05-2022
Total budget - Public funding: 3 590 354,52 Euro - 3 590 354,00 Euro
Cordis data

Original description

Brain conditions such as neurodegenerative diseases, stroke and traumatic injuries are a mayor burden in modern society. Because neural stem cells (NSCs) can differentiate into new neural cells including neurons, the regulation of their proliferation, differentiation and migration represent a promising regenerative/therapeutic strategy. The hypothesis of NanoStem project is that novel nanoparticles (NPs) combined with recent identified/developed pharmaceuticals can be an efficient approach to control the biological activity of NSCs. The scientific project is organized in three work packages (WP), each focusing on specific objectives and containing well-defined deliverables. WP1 will focus on the synthesis of the nanomaterials and the uploading of the therapeutics. WP2 will take the best nanoparticles and focus more on the evaluation of the permeation and efficacy of the formulations against NSCs. WP3 will focus on in vivo studies to evaluate the formulations developed to tackle the brain and to assess their toxicity. The project will train 14 ESRs in areas including organic and polymer chemistry, cell biology, pharmacology, neuroscience, nanobiotechnology and clinical sciences. The project will also provide a substantial training program in complementary skills, targeting both professional and personal development, and translation of research and entrepreneurship. The project brings together six academic partners, one hospital and two industrial teams as full partners, complemented by four associate partners, one of which is an industrial team, distributed over a total of seven European Union member states. The consortium brings together groups with a very interdisciplinary expertise ranging from nanoparticle synthesis and characterization, computational modeling, in vitro BBB models and BBB transport, neural stem cells, animal testing and clinical expertise.

Status

CLOSED

Call topic

MSCA-ITN-2017

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.1. Fostering new skills by means of excellent initial training of researchers
H2020-MSCA-ITN-2017
MSCA-ITN-2017